Compare FBK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | WVE |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2016 | 2015 |
| Metric | FBK | WVE |
|---|---|---|
| Price | $55.02 | $7.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $62.75 | $30.25 |
| AVG Volume (30 Days) | 283.7K | ★ 5.9M |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $43.54 | N/A |
| Revenue Next Year | $7.86 | $85.67 |
| P/E Ratio | $23.04 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $39.47 | $5.02 |
| 52 Week High | $62.37 | $21.73 |
| Indicator | FBK | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 30.12 |
| Support Level | $51.79 | $6.66 |
| Resistance Level | $56.30 | $8.29 |
| Average True Range (ATR) | 1.14 | 0.61 |
| MACD | 0.69 | -0.08 |
| Stochastic Oscillator | 72.98 | 27.65 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.